1,499 reports of this reaction
3.1% of all GALCANEZUMAB GNLM reports
#7 most reported adverse reaction
INJECTION SITE HAEMORRHAGE is the #7 most commonly reported adverse reaction for GALCANEZUMAB GNLM, manufactured by Eli Lilly and Company. There are 1,499 FDA adverse event reports linking GALCANEZUMAB GNLM to INJECTION SITE HAEMORRHAGE. This represents approximately 3.1% of all 49,086 adverse event reports for this drug.
Patients taking GALCANEZUMAB GNLM who experience injection site haemorrhage should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INJECTION SITE HAEMORRHAGE is moderately reported among GALCANEZUMAB GNLM users, representing a notable but not dominant share of adverse events.
In addition to injection site haemorrhage, the following adverse reactions have been reported for GALCANEZUMAB GNLM:
The following drugs have also been linked to injection site haemorrhage in FDA adverse event reports:
INJECTION SITE HAEMORRHAGE has been reported as an adverse event in 1,499 FDA reports for GALCANEZUMAB GNLM. This does not prove causation, but indicates an association observed in post-market surveillance data.
INJECTION SITE HAEMORRHAGE accounts for approximately 3.1% of all adverse event reports for GALCANEZUMAB GNLM, making it a notable side effect.
If you experience injection site haemorrhage while taking GALCANEZUMAB GNLM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.